Literature DB >> 16540768

The epidemiology of nonalcoholic fatty liver disease in adults.

Jeanne M Clark1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that has been shown to progress to cirrhosis and hepatocellular carcinoma. This article reviews the prevalence of NAFLD and the factors associated this disorder, and with the more advanced stages of NAFLD, including nonalcoholic steatohepatitis (NASH) and fibrosis. In the general population, the estimated prevalence ranges from 3% to 24%, with most estimates in the 6% to 14% range. NAFLD is extremely common among patients undergoing bariatric surgery, ranging from 84% to 96%. In these patients, 25% to 55% have NASH, 34% to 47% have fibrosis, and 2% to 12% have bridging fibrosis or cirrhosis. NAFLD appears to be most strongly associated with obesity, and insulin resistance states including diabetes and with other features of the metabolic syndrome, such as high triglycerides and low HDL. It appears to be more common in men, and it increases with increasing age and after menopause. Some data suggest that Mexican Americans are more likely to have NAFLD and blacks are less likely compared with non-Hispanic whites. More advanced stages of NAFLD are associated with older age, higher body mass index, diabetes, hypertension, high triglycerides, and/or insulin resistance. An AST/ALT ratio greater >1 may also indicate more severe disease. Although hepatocellular carcinoma can occur in the setting of NAFLD, the risk factors for hepatocellular carcinoma in the setting of NAFLD have not been established. More prospective studies are needed to determine the true risk factors for the development and progression of NAFLD to help identify patients at highest risk who might benefit from treatment trials.

Entities:  

Mesh:

Year:  2006        PMID: 16540768     DOI: 10.1097/01.mcg.0000168638.84840.ff

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  283 in total

1.  NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis.

Authors:  Tarsila Ribeireiro; James Swain; Michael Sarr; Michael Kendrick; Florencia Que; Schuyler Sanderson; Anuradha Krishnan; Kimberly Viker; Kymberly Watt; Michael Charlton
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

2.  Focal Fatty liver: more than just a radiographic curiosity?

Authors:  Heather M Patton; Joel E Lavine
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

3.  NASH: Thiazolidinediones for NASH--one pill doesn't fix everything.

Authors:  Brent A Neuschwander-Tetri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05       Impact factor: 46.802

4.  Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease.

Authors:  Maria Stepanova; Noreen Hossain; Arian Afendy; Kellie Perry; Zachary D Goodman; Ancha Baranova; Zobair Younossi
Journal:  Obes Surg       Date:  2010-01-30       Impact factor: 4.129

5.  From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways.

Authors:  Enzo Ierardi; Rosa Rosania; Mariangela Zotti; Floriana Giorgio; Simonetta Prencipe; Nicola Della Valle; Vincenzo De Francesco; Carmine Panella
Journal:  World J Gastrointest Oncol       Date:  2010-06-15

6.  A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting.

Authors:  Sarah E Hugo; Lourdes Cruz-Garcia; Santhosh Karanth; Ryan M Anderson; Didier Y R Stainier; Amnon Schlegel
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

7.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

8.  Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.

Authors:  N S Patel; M R Peterson; D A Brenner; E Heba; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

9.  Dissociation of hepatic insulin resistance from susceptibility of nonalcoholic fatty liver disease induced by a high-fat and high-carbohydrate diet in mice.

Authors:  Akihiro Asai; Pauline M Chou; Heng-Fu Bu; Xiao Wang; M Sambasiva Rao; Anthony Jiang; Christine J DiDonato; Xiao-Di Tan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-01-16       Impact factor: 4.052

10.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.